Telepsychiatry's Time Has Come for Rural Patients

2006 ◽  
Vol 36 (15) ◽  
pp. 31
Author(s):  
DAMIAN MCNAMARA
Keyword(s):  
2012 ◽  
Vol 45 (11) ◽  
pp. 13
Author(s):  
NASEEM S. MILLER
Keyword(s):  

2012 ◽  
Author(s):  
K. Bryant Smalley ◽  
Jacob C. Warren ◽  
Lisa Watson-Johnson ◽  
Nikki Barefoot ◽  
Sean Fowler

2006 ◽  
Vol 34 (8) ◽  
pp. 30
Author(s):  
DAMIAN MCNAMARA
Keyword(s):  

2012 ◽  
Vol 42 (11) ◽  
pp. 42
Author(s):  
NASEEM S. MILLER
Keyword(s):  

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 21-OR
Author(s):  
ELIZABETH A. KOBE ◽  
ALLISON LEWINSKI ◽  
SUSANNE DANUS ◽  
ELISABETH L. SIDOLI ◽  
BETH GRECK ◽  
...  

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii79-ii79
Author(s):  
Kathryn Nevel ◽  
Samuel Capouch ◽  
Lisa Arnold ◽  
Katherine Peters ◽  
Nimish Mohile ◽  
...  

Abstract BACKGROUND Patients in rural communities have less access to optimal cancer care and clinical trials. For GBM, access to experimental therapies, and consideration of a clinical trial is embedded in national guidelines. Still, the availability of clinical trials to rural communities, representing 20% of the US population, has not been described. METHODS We queried ClinicalTrials.gov for glioblastoma interventional treatment trials opened between 1/2010 and 1/2020 in the United States. We created a Structured Query Language database and leveraged Google application programming interfaces (API) Places to find name and street addresses for the sites, and Google’s Geocode API to determine the county location. Counties were classified by US Department of Agriculture Rural-Urban Continuum Codes (RUCC 1–3 = urban and RUCC 4–9 = rural). We used z-ratios for rural-urban statistical comparisons. RESULTS We identified 406 interventional treatment trials for GBM at 1491 unique sites. 8.7% of unique sites were in rural settings. Rural sites opened an average of 1.7 trials/site and urban sites 2.8 trials/site from 1/2010–1/2020. Rural sites offered more phase II trials (63% vs 57%, p= 0.03) and fewer phase I trials (22% vs 28%, p= 0.01) than urban sites. Rural locations were more likely to offer federally-sponsored trials (p< 0.002). There were no investigator-initiated or single-institution trials offered at rural locations, and only 1% of industry trials were offered rurally. DISCUSSION Clinical trials for GBM were rarely open in rural areas, and were more dependent on federal funding. Clinical trials are likely difficult to access for rural patients, and this has important implications for the generalizability of research as well as how we engage the field of neuro-oncology and patient advocacy groups in improving patient access to trials. Increasing the number of clinical trials in rural locations may enable more rural patients to access and enroll in GBM studies.


1991 ◽  
Vol 84 (Supplement) ◽  
pp. 25
Author(s):  
George Lindbeck ◽  
David Groopman ◽  
Robert Powers

Sign in / Sign up

Export Citation Format

Share Document